Please use this identifier to cite or link to this item:
Title: Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy.
Austin Authors: Broadley, Simon A;Barnett, Michael H;Boggild, Mike;Brew, Bruce J;Butzkueven, Helmut;Heard, Robert;Hodgkinson, Suzanne;Kermode, Allan G;Lechner-Scott, Jeannette;Macdonell, Richard A L ;Marriott, Mark;Mason, Deborah F;Parratt, John;Reddel, Stephen W;Shaw, Cameron P;Slee, Mark;Spies, Judith;Taylor, Bruce V;Carroll, William M;Kilpatrick, Trevor J;King, John;McCombe, Pamela A;Pollard, John D;Willoughby, Ernest
Affiliation: Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
Hunter Medical Research Institute, The University of Newcastle, New Lambton, NSW, Australia
South Western Sydney Clinical School, University of New South Wales, NSW, Australia
Westmead Clinical School, University of Sydney, NSW, Australia
Department of Neurology and St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, University of New South Wales, Darlinghurst, NSW, Australia
Department of Neurology, The Townsville Hospital, Douglas, QLD, Australia
Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
School of Medicine, Griffith University, Gold Coast Campus, QLD 4222, Australia
School of Medicine, Deakin University, Victoria, Australia
Department of Neurology, Gold Coast University Hospital, Southport, QLD, Australia
Centre for Neuromuscular and Neurological Disorders, University of Western Australia, WA, Australia
Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
Central Clinical School, University of Sydney, NSW, Australia
Flinders Medical Centre, Flinders University, SA, Australia
Menzies Research Institute, University of Tasmania, TAS, Australia
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia
Institute of Immunology and Infectious Diseases, Murdoch University, WA, Australia
Department of Neurology, Eastern Health and Monash University, 2/5 Arnold Street, Box Hill VIC 3128, Australia
University of Queensland Centre for Clinical Research, QLD, Australia
Department of Neurology, Christchurch Hospital, Christchurch, New Zealand.
Department of Neurology, Auckland City Hospital, Auckland, New Zealand.
Issue Date: 28-Jun-2014
Publication information: Journal of Clinical Neuroscience 2014; 21(11): 1847-56
Abstract: In Part 2 of this three part review of multiple sclerosis (MS) treatment with a particular focus on the Australian and New Zealand perspective, we review the newer therapies that have recently become available and emerging therapies that have now completed phase III clinical trial programs. We go on to compare the relative efficacies of these newer and emerging therapies alongside the existing therapies. The effectiveness of β-interferon in the treatment of different stages and the different disease courses of MS is critically reviewed with the conclusion that the absolute level of response in term of annualised relapse rates (where relapses occur) and MRI activity are similar, but are disappointing in terms of sustained disability progression for progressive forms of the disease. Finally we review the controversial area of combination therapy for MS. Whilst it remains the case that we have no cure or means of preventing MS, we do have a range of effective therapies that when used appropriately and early in the disease course can have a significant impact on short term and longer term outcomes.
Gov't Doc #: 24986155
DOI: 10.1016/j.jocn.2014.01.018
Journal: Journal of Clinical Neuroscience
Type: Journal Article
Subjects: Evidence-based medicine
Multiple sclerosis
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 27, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.